Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tesnatilimab in Moderately to Severely Active Crohn's Disease
NCT02877134Phase 2Completed
- Sponsor
- Janssen Pharmaceutical
- Start
- Aug 2016
- Primary completion
- Dec 2020
- Modality
- Monoclonal Antibodies
- Countries
- 14
01
Overview
A Phase 2 trial of NNC0142-0002 in Crohn's disease, sponsored by Janssen Pharmaceutical. Started Aug 2016; status: completed.
02
Drugs
NNC0142-0002
03
Conditions
Crohn's disease
Beyond the preview
Go deeper on NCT02877134.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02877134.